Hutchmed (China) Limited Blocklisting Six Monthly Return (1094Y)

TIDMHCM

RNS Number : 1094Y

Hutchmed (China) Limited

29 December 2023

Blocklisting Six Monthly Return

Hong Kong, Shanghai, & Florham Park, NJ - Friday, December 29, 2023: HUTCHMED (China) Limited (" HUTCHMED " or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:

 
1.   Name of applicant:            HUTCHMED (China) Limited 
2.   Name of scheme:               (a)   Share Option Scheme conditionally adopted 
                                          by HUTCHMED in 2005 ("2005 HUTCHMED 
                                          Share Option Scheme") 
                                   (b)   Share Option Scheme conditionally adopted 
                                          by HUTCHMED in 2015 ("2015 HUTCHMED 
                                          Share Option Scheme") 
3.   Period of return:             From June 29, 202 3 to December 28, 202 
                                    3 
4.   Balance under scheme          (a)   2005 HUTCHMED Share Option Scheme: 434,050 
      from previous return:               ordinary shares of US$0.1 each 
                                   (b)   2015 HUTCHMED Share Option Scheme: 51,730,718 
                                          ordinary shares of US$0.1 each 
5.   The amount by which           (a)   2005 HUTCHMED Share Option Scheme: Nil 
      the block scheme has 
      been increased, if 
      the scheme has been 
      increased since the 
      date of the last return: 
                                   (b)   2015 HUTCHMED Share Option Scheme: Nil 
6.   Number of securities          (a)   2005 HUTCHMED Share Option Scheme: 211,320 
      issued/allotted under 
      scheme during period: 
                                   (b)   2015 HUTCHMED Share Option Scheme: 4,883,500 
7.   Balance under scheme          (a)   2005 HUTCHMED Share Option Scheme: 222,730 
      not yet issued/allotted             ordinary shares of US$0.1 each (Note: 
      at end of the period:               All granted share options have been 
                                          exercised) 
                                   (b)   2015 HUTCHMED Share Option Scheme: 46,847,218 
                                          ordinary shares of US$0.1 each 
8.   Number and class of           25,198,880 ordinary shares of US$0.1 each 
      securities originally         admitted on June 17, 2019 ( to replace 
      listed and the date           the Company's previous block admission 
      of admission:                 schemes following the Company's share subdivision 
                                    which took effect on May 30, 2019) 
 
 
 
 
9.   Total number of securities    871,256,270 ordinary shares of US$0.1 each 
      in issue at the end 
      of the period: 
Name of contact:                   Weiguo Su 
Address of contact:                Level 18, The Metropolis Tower, 10 Metropolis 
                                    Drive, Hung Hom, Kowloon, Hong Kong 
Telephone number of contact:       +852 2121 8200

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on LinkedIn .

CONTACTS

 
Investor Enquiries                                           +852 2121 8200 / +1 973 306 4490 / ir@hutch-med.com 
 
Media Enquiries 
Ben Atwell / Alex Shaw, FTI Consulting                       +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 
                                                             545 055 (Mobile) / HUTCHMED@fticonsulting.com 
Zhou Yi, Brunswick                                           +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com 
 
Nominated Advisor 
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure 
 Gordon                                                      +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLREASAPAAKDFFA

(END) Dow Jones Newswires

December 29, 2023 03:30 ET (08:30 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024